Tagitanlimab
- Generic Name
- Tagitanlimab
- Drug Type
- Biotech
- CAS Number
- 2417649-97-7
- Unique Ingredient Identifier
- GUY458P83P
SKB264 +/- KL-A167 in Recurrent or Metastatic HER2-negative Breast Cancer
Phase 2
Recruiting
- Conditions
- Triple-negative Breast Cancer and HR+/HER2- BC
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2023-10-23
- Target Recruit Count
- 175
- Registration Number
- NCT05445908
- Locations
- 🇨🇳
Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Jiangsu Province Hospital, Nanjing, Jiangsu, China
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Phase 2
Recruiting
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2023-12-14
- Target Recruit Count
- 110
- Registration Number
- NCT05351788
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, China
KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma
Phase 3
Active, not recruiting
- Conditions
- Recurrent or MetastaticNasopharyngeal Carcinoma
- Interventions
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2023-10-23
- Target Recruit Count
- 295
- Registration Number
- NCT05294172
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma
- First Posted Date
- 2018-07-09
- Last Posted Date
- 2023-10-23
- Target Recruit Count
- 109
- Registration Number
- NCT03580564
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath